Chemotherapy in Recurrent Epithelial Ovarian Cancer (EOC): An Analysis of Prognostic Factors

• DOI: 10.1111/j.1447-0756.2000.tb01314.x
• Publication Date: 2010-05-26T20:51:06Z
• Authors: S. Shamsunder; Lalit Kumar; S. Gupta; S. Kumar; N. Bhatla; R. Singh; V. Kochupillai
• Keywords: Adult; Ovarian Neoplasms; Paclitaxel; Middle Aged; Prognosis; 3. Good health; Survival Rate; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Doxorubicin; Antineoplastic Combined Chemotherapy Protocols; Humans; Female; Cisplatin; Neoplasm Recurrence, Local; Cyclophosphamide; Aged; Retrospective Studies

Abstract Objective: Prognosis of patients with recurrent epithelial ovarian cancer (EOC) is generally poor. Cisplatin the most effective drug. We used three cisplatin based chemotherapeutic (CT) regimens and retrospectively analyzed data to determine response rate, toxicity, survival impact various prognostic factors on outcome. Patients Methods: Between August, 1989 September, 1997, 102 were diagnosed have EOC. Sixty‐five received CT every 3 weeks using 75 mg/m 2 IV day 1 plus cyclophosphamide 750 (CP, Group A, n = 29), 1, adriamycin 40 (CAP, B, 22) paclitaxel 135 (TP, C, 14). Twelve single agent not analyzed. Remaining 25 refused treatment followed for survival. Results: The overall rate (complete partial) was 59.2% receiving CP (Group A), 45% CAP B) 76.9% those TP C), p ns. Response significantly higher platinum sensitive disease compared resistant disease; 55.76 vs 39%, < 0.007. tolerated well; died one each in A (CP) C (TP), respectively. median from date relapse chemotherapy 15 months 4 who did receive chemotherapy, 0.001. Chemotherapy responders had a than non‐responders, 24 10 months, 0.01. different groups; A‐15 B‐12 0.738. On univariate analysis — time since last (< 6 > 0.037, previous CT, 0.0183, cisplatinum sensitivity resistance, 0.032, number sites 2) recurrence, 0.004 salvage 0.01 associated benefit. multivariate analysis, attained significance. Conclusions: Our study confirms benefit disease, responding most.